1. Home
  2. NA vs BYSI Comparison

NA vs BYSI Comparison

Compare NA & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NA

Nano Labs Ltd

HOLD

Current Price

$1.93

Market Cap

43.4M

Sector

Technology

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$0.73

Market Cap

35.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NA
BYSI
Founded
2019
2010
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.4M
35.8M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
NA
BYSI
Price
$1.93
$0.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.5K
1.9M
Earning Date
03-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$0.67
52 Week High
$6.30
$2.44

Technical Indicators

Market Signals
Indicator
NA
BYSI
Relative Strength Index (RSI) 52.31 32.00
Support Level $1.64 N/A
Resistance Level $1.96 $1.30
Average True Range (ATR) 0.09 0.12
MACD 0.01 -0.00
Stochastic Oscillator 81.25 8.79

Price Performance

Historical Comparison
NA
BYSI

About NA Nano Labs Ltd

Nano Labs Ltd is a Web 3.0 infrastructure and product solution provider, as well as a crypto treasury company. It is focused on the development of HTC chips and HPC chips. In addition, the company has established BNB value investment and adopted BNB (a crypto token) as the primary reserve asset. Furthermore, it has launched the iPollo Claw, a dedicated hardware solution for the OpenClaw AI Agent Ecosystem. Nano Labs derives revenue mainly from its HTC and HPC offerings, which comprise Darkbird series HPC chips that feature high performance and high energy consumption efficiency, and Cuckoo series chips, used in GPUs. Geographically, the company generates maximum revenue from the People's Republic of China (PRC), and the rest from Singapore, Hong Kong, the United States, and other markets.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: